KRAS and neoplasm: This was independent of the KRAS/BRAF mutation status and EGFR expression levels of tumor cells, thus suggesting that resistance mechanisms observed with the therapeutic agents targeting EGFR activity and signaling may not be relevant in this setting (Figure 4) (241).